Caplin Point Laboratories (NSE:CAPLIPOINT) Other Stockholders Equity: ₹35,712 Mil (As of Mar. 2026)


NSE:CAPLIPOINT Caplin Point Laboratories Ltd NSE:CAPLIPOINT
87 GF Score
Price ₹2,583.60
GF Value ₹2,083.88
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Caplin Point Laboratories Other Stockholders Equity?

Caplin Point Laboratories NSE:CAPLIPOINT -1.44% 87 Other Stockholders Equity is ₹35,712 Mil as of Mar. 2026. GuruFocus rates NSE:CAPLIPOINT with a GF Score™ of 87/100 and a GF Value™ of ₹2,083.88 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Caplin Point Laboratories's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹35,712 Mil.

Caplin Point Laboratories's quarterly Other Stockholders Equity declined from Sep. 2025 (₹31,442 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹35,712 Mil).

Caplin Point Laboratories's annual Other Stockholders Equity increased from Mar. 2024 (₹1,804 Mil) to Mar. 2025 (₹3,050 Mil) and increased from Mar. 2025 (₹3,050 Mil) to Mar. 2026 (₹35,712 Mil).

Caplin Point Laboratories Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Caplin Point Laboratories's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caplin Point Laboratories Other Stockholders Equity Chart

Caplin Point Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,209.50 1,701.10 1,804.10 3,049.80 35,712.20

Caplin Point Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,049.80 0.00 31,441.50 0.00 35,712.20
NSE:CAPLIPOINT
87GF Score
Caplin Point Laboratories Ltd NSE:CAPLIPOINT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caplin Point Laboratories Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹35,712 Mil mean?
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Other Stockholders Equity of ₹35,712 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Caplin Point Laboratories and its competitors.
Is Caplin Point Laboratories' Other Stockholders Equity too high?
Caplin Point Laboratories' current Other Stockholders Equity is ₹35,712 Mil. Overall, Caplin Point Laboratories has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Other Stockholders Equity compare to ZTS and UTHR?
Caplin Point Laboratories' Other Stockholders Equity of ₹35,712 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Caplin Point Laboratories and its competitors. Caplin Point Laboratories's current Other Stockholders Equity is ₹35,712 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,083.88, compared to a current price of ₹2,583.60 — trading 24% above its estimated fair value. The current Other Stockholders Equity is ₹35,712 Mil. Caplin Point Laboratories' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Other Stockholders Equity is ₹35,712 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?

Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued. The current stock price of ₹2,583.60 is trading 24% above its estimated GF Value™ of ₹2,083.88. GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:CAPLIPOINT:

  • Other Stockholders Equity: ₹35,712 Mil
  • GF Value™: ₹2,083.88 vs. price of ₹2,583.60 (24% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caplin Point Laboratories Business Description

Other Exchanges 524742:India
Address Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
87GF Score

Get the complete analysis for NSE:CAPLIPOINT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,583.60
Price
₹2,083.88
GF Value